ITGR · Integer Holdings Corporation · Stock research

Current Thesis

The equity has traded as a deal instrument since 2026-08-03, when KKR's affiliate signed an all-cash agreement at $127.00 per share, enterprise value approximately $5.7B, board unanimous, no financing condition. The last completed daily close was $125.20 (2026-08-21) — $1.80 beneath the stated consideration, about 1.4% of that close. Two weeks earlier the close was $125.27 (2026-08-07). The gap has gone essentially nowhere: the market is pricing high completion odds and paying nothing for a topping bid. What an investor buys here is a countdown to a year-end 2026 closing guide against a 2027-05-02 outside date, with the equity's remaining headline upside contractually fixed.

The refresh point since the last note: the deal has entered its paperwork stage and the paperwork has not arrived. No PREM14A or DEFM14A merger proxy appears on Integer's SEC filing index as of 2026-08-22, and no 8-K has disclosed an HSR filing date or clearance.

Bullish and bearish views on Integer Holdings Corporation

The model's bull view on Integer Holdings Corporation (ITGR), in brief: Terms are signed, not proposed (2026-08-03): $127 cash, EV ~$5.7B, funded with equity from KKR-managed funds plus committed debt; lead arrangers named in the announcement were Citi, KKR Capital Markets, Barclays, UBS and Jefferies. The bear view: Upside is capped at $1.80. At the 2026-08-21 close there is no fundamental path above $127 while this agreement stands, and no competing bidder has surfaced in the 19 days since signing. Sell-side is now fully collapsed onto the deal. KeyBanc to Sector Weight (2026-08-03)… Both cases follow in full.

Bull Case

• Terms are signed, not proposed (2026-08-03): $127 cash, EV ~$5.7B, funded with equity from KKR-managed funds plus committed debt; lead arrangers named in the announcement were Citi, KKR Capital Markets, Barclays, UBS and Jefferies. No financing contingency.
• Fee asymmetry sits with the seller: parent reverse termination fee $307M against a $154M company fee, per merger-agreement exhibits to the 2026-08-03 8-K. Against ~$5.7B of EV the company fee is not a prohibitive toll on a competing bid.
• The spread has held through two weeks of nothing. From the 2026-08-07 close of $125.27 to the 2026-08-21 close of $125.20, price moved seven cents. Deal breaks are usually preceded by spread widening; none is visible in the endpoints.
• The Q2 print cleared consensus into signing: sales $464.110M vs $450.505M, adjusted EPS $1.60 vs $1.42 (2026-08-03), with the 10-Q filed 2026-08-04. A quarter that beats weakens any later material-adverse-effect argument.
• Sponsor buyer, no device-manufacturing overlap. The horizontal-overlap route to an antitrust problem is narrower than in a strategic deal. That is an inference from the buyer's identity; no regulatory position has been disclosed either way.
• Calendar slack: roughly nine months of runway between signing and the 2027-05-02 outside date against a year-end guide.

Bear Case

• Upside is capped at $1.80. At the 2026-08-21 close there is no fundamental path above $127 while this agreement stands, and no competing bidder has surfaced in the 19 days since signing.
• Sell-side is now fully collapsed onto the deal. KeyBanc to Sector Weight (2026-08-03); Oppenheimer to Perform (2026-08-04); Truist to Hold, PT $127; Wells Fargo Equal-Weight, PT $127 (both 2026-08-04); Benchmark to Hold on 2026-08-14. Five houses neutralized, two targets set exactly at the consideration. MarketBeat's aggregate showed a consensus Hold as of 2026-08-19.
• The un-deal anchors are far below. Pre-leak marks: Citi Neutral PT $96 (2026-07-08), Truist Buy PT $110 (2026-07-16) — roughly 12% to 23% under the 2026-08-21 close.
• The standalone business is contracting. Q2 2026 sales fell 2.6% YoY, organic sales -1.5%, and Integer withdrew its FY2026 outlook on 2026-08-03 and cancelled the 2026-08-06 call. No company forecast exists to underwrite a break price.
• Funding still has to clear a market. No financing condition is a contractual protection; a ~$5.7B EV take-private — InsideArbitrage put the purchase at 16.36x EBITDA in its 2026-08 write-up — still meets the loan and high-yield bid between signing and funding.

Setup & Price Structure

The shares are up 40.2% over three months and sit 0.7% below the 52-week high of $126.07 — a step function from the 2026-07-31 WSJ leak (halted on an upside circuit breaker, up 11.05% intraday) and the 2026-08-03 signing, not a trend. The 52-week high itself sits $0.93 under the consideration; the tape has never paid full price.

The narrative is maturing. The event is well known and still working. RSI(14) has decayed from 95.6 on 2026-08-07 to 60.7 on 2026-08-21 while price held within seven cents — the momentum reading normalized without any price given back, which is how a pinned deal stock behaves. Fresh attention has moderated: after seven news items in the 2026-07-31 to 2026-08-04 window, the only rating action in the following two weeks was Benchmark on 2026-08-14. The label flips to saturated if screen-driven coverage rebuilds while the spread stays inside 1.5%, and to dead on a disclosed second request or a break.

Crowding and positioning observables, stated as observables: a Schedule 13G disclosing a 5.4% position by Nomura Group appears on the filing index dated 2026-08-14 (a passive-holder form; Nomura Group filings aggregate broker-dealer and derivative books, so it is not by itself evidence of directional arbitrage accumulation). Insider activity on file is July RSU grant-and-vest mechanics for Metcalf, Kirk and Harris (Form 4s 2026-07-01 and 2026-07-10) — no open-market sales reported. There is no earnings date to trade into: the Q2 call was cancelled and guidance withdrawn. Momentum and 52-week-high screens will keep surfacing a security whose headline reward is $1.80.

Catalyst Calendar (next 30 days)

• ~2026-09-02 (est.) — preliminary merger proxy (PREM14A). Not on file as of 2026-08-22. Sets the special-meeting date and discloses the background of the merger, the financial analysis, and the full deal-protection package including any go-shop or matching rights.
• ~2026-09-15 (est.) — expiry of the HSR initial 30-day waiting period. The filing date has not been disclosed, so this estimate hangs off the 2026-08-03 signing. A clean expiry supports the year-end guide; a second request pushes toward 2027-05-02.
• Nothing confirmed-dated falls inside the next 30 days. Both items above are estimates, and the absence of a scheduled event is itself the current state of the file.

What Would Change Our Mind

The calendar breaks before the price does. If 2026-09 closes with no merger proxy on file, the special meeting slides toward Q4 and the year-end 2026 closing guide stops being credible on arithmetic alone — that, or an 8-K disclosing an HSR second request, is what turns a 1.4% spread into a re-underwriting. On price, a daily close below $118 — more than a 7% discount to the $127 consideration, well outside the band a committed no-financing-condition deal trades in — would mark the market repricing completion odds rather than merely drifting. In the other direction, a competing proposal disclosed in the proxy background, or a stated bid above $127, would reopen an upside the current terms foreclose. Passing 2026-12-31 without a close and without a restated target grades the timeline as slipped even if the spread holds.

Correlation Notes

• The name has decoupled from the medtech contract-manufacturing complex. Whatever that group did between 2026-08-07 and 2026-08-21 did not reach this price; the endpoints moved seven cents. The live correlates are deal-specific.
• The relevant macro sensitivity is credit rather than device end-markets: funding for a ~$5.7B EV take-private is exposed to leveraged-loan and high-yield conditions between signing and closing, even with no financing condition in the agreement.
• A secondary correlate is the sponsor take-private pipeline and antitrust stance toward financial buyers; a visible second request elsewhere in large-cap LBO land would widen this spread by association rather than by anything Integer disclosed.
• On a break, the equity re-correlates hard to its own fundamentals — Q2 sales -2.6% YoY, organic -1.5%, no FY2026 outlook — and toward the pre-leak $96–$110 analyst zone.